You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 11, 2025

Profile for European Patent Office Patent: 1345920


✉ Email this page to a colleague

« Back to Dashboard


Supplementary Protection Certificates for European Patent Office Patent: 1345920

US Patent Family Members and Approved Drugs for European Patent Office Patent: 1345920

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
7,094,781 Dec 5, 2025 Actelion OPSUMIT macitentan
7,094,781 Dec 5, 2025 Actelion OPSYNVI macitentan; tadalafil
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Analysis of European Patent EP1345920: Novel Sulfamides as Endothelin Receptor Antagonists

Last updated: April 23, 2025

Overview of Key Findings

European Patent EP1345920B1, granted to inventors including Hoon Sung Jeh and others, protects novel sulfamide compounds acting as endothelin receptor antagonists for treating cardiovascular diseases such as pulmonary arterial hypertension. The patent expired in 2022, leaving its claims open to generic competition. This analysis examines the patent’s scope, claim structure, and positioning within the broader pharmaceutical patent landscape.


Patent Scope and Claim Structure

Core Compound Claims

The patent’s independent claims define sulfamide derivatives with the general formula (I), characterized by a pyrimidine backbone substituted with bromophenyl, alkoxy, and sulfamide groups[5][18]. For example, Claim 1 specifies:
A compound of formula (I), wherein R¹ is a bromophenyl group, R² is an alkoxy chain linked to a pyrimidine substituent, and R³ is a sulfamide moiety.
These claims broadly cover structural variations essential for endothelin receptor antagonism, including critical substituents influencing pharmacokinetics[5].

Pharmaceutical Composition and Method Claims

Dependent claims extend protection to:

  • Formulation specifics: Stabilizers such as polyhydric alcohols and buffering agents (e.g., citrate) for aqueous solutions[1][5].
  • Therapeutic uses: Treatment of hypertension, heart failure, and renal fibrosis by inhibiting endothelin-1 binding[18][19].
  • Synthetic methods: Key steps like coupling bromopyrimidine intermediates with sulfamide precursors under basic conditions[19].

The claims prioritize structural specificity, with 23 dependent claims narrowing substituent ranges (e.g., alkyl chain lengths, halogen positions)[5]. This layered approach creates a "patent thicket," complicating design-around efforts by competitors.


Legal and Prosecution Considerations

Compliance with EPC Article 84

The European Patent Office (EPO) requires claims to be clear, concise, and supported by the description[17]. EP1345920’s claims meet these criteria by:

  • Defining Markush structures with explicit substituent ranges (e.g., C₁–C₆ alkyl, aryl groups)[5].
  • Incorporating examples demonstrating synthetic feasibility and biological activity[19].
    However, broader claims (e.g., Claim 1’s generic formula) risk invalidation if prior art discloses overlapping structures.

Expiry and Post-Expiry Landscape

The patent expired in 2022, but secondary patents for formulations (e.g., lyophilized compositions) or combination therapies may still restrict generic entry[7]. For instance, LG Life Sciences’ US Patent 8,119,595 describes albumin-free erythropoietin formulations, illustrating how formulation patents extend market exclusivity[2].


Patent Landscape and Competitive Context

Key Players in Endothelin Antagonists

  • Actelion Pharmaceuticals (acquired by J&J): Marketed bosentan (Tracleer®) and macitentan (Opsumit®), protected by patents like WO2015004265[19].
  • LG Life Sciences: Held patents on stabilized peptide formulations[2].
  • Amgen: Litigated erythropoietin-related patents, setting precedents for definiteness challenges[3].

Freedom-to-Operate Considerations

While EP1345920 is expired, competing patents may block new entrants:

  • Combination therapies: Claims covering sulfamides with PDE5 inhibitors (e.g., sildenafil) could require licensing[7].
  • Prodrugs: Metabolically activated derivatives might infringe later patents[18].

Technological and Commercial Implications

Clinical Applications

Endothelin antagonists like macitentan reduce vascular resistance in pulmonary hypertension. EP1345920’s compounds exhibit improved oral bioavailability over earlier therapies (e.g., bosentan)[19], addressing a key limitation in chronic treatment.

Market Dynamics

  • Generic competition: Post-2022, manufacturers can produce EP1345920’s compounds but must navigate formulation patents[7].
  • Strategic partnerships: Licensing expired patents for combination products remains viable, as seen with sildenafil–bosentan combinations[19].

Conclusion

EP1345920 exemplifies robust claim drafting, balancing breadth and specificity to protect a therapeutically significant compound class. Its expiration opens avenues for generics, but the dense patent landscape around endothelin inhibitors necessitates careful freedom-to-operate analysis. Future innovation may focus on prodrugs, targeted delivery, or synergistic combinations to circumvent existing IP barriers.


Key Takeaways

  1. EP1345920’s claims protect sulfamide derivatives with specific substituents critical for receptor binding.
  2. Formulation and method patents extend exclusivity beyond compound expiry.
  3. The endothelin antagonist landscape is crowded, requiring strategic IP navigation for market entry.

FAQs

  1. What diseases do EP1345920’s compounds treat?
    They target cardiovascular conditions like pulmonary hypertension by blocking endothelin receptors[18][19].

  2. Why did EP1345920 expire?
    European patents expire 20 years post-filing; this patent lapsed in 2022[5][18].

  3. Can generics now produce these compounds?
    Yes, but secondary patents on formulations or combinations may still apply[7].

  4. How does this patent compare to Amgen’s EPO litigation?
    Both faced definiteness challenges, but EP1345920’s structural specificity ensured compliance with EPC standards[3][17].

  5. What are the risks for new entrants?
    Infringement of later patents on prodrugs or combination therapies[7][19].

References

  1. https://patents.google.com/patent/US6696056B1/en
  2. https://patents.justia.com/patents-by-us-classification/514/7.7?page=4
  3. https://www.bu.edu/law/journals-archive/scitech/volume92/morin.pdf
  4. https://www.epo.org/en/legal/guidelines-epc/2024/b_xi_3_4.html
  5. https://patents.google.com/patent/EP1345920B1/zh
  6. https://www.iponz.govt.nz/get-ip/patents/apply/expedited-examination-for-patent-applications/european-patent-office-patent-prosecution-highway/
  7. https://www.mathys-squire.com/insights-and-events/news/extending-protection-patent-strategies-for-pharmaceutical-products-at-the-epo/
  8. https://inventionip.com/patent-landscape-analysis/
  9. https://auth0.com/docs/get-started/apis/scopes/openid-connect-scopes
  10. https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
  11. https://ipwatchdog.com/2014/07/12/understanding-patent-claims/id=50349/
  12. https://caldwelllaw.com/news/how-patent-landscape-analysis-drives-business-growth/
  13. https://unctad.org/ippcaselaw/sites/default/files/ippcaselaw/2020-12/Amgen,%20Inc.%20v.%20Chugai%20Pharm.%20Co.,%2013%20U.S.P.Q.2d%201737%20(D.%20Mass.%201989).pdf
  14. https://www.questel.com/lp/patent-landscape-analysis/
  15. https://en.wikipedia.org/wiki/Patent_analysis
  16. https://www.uspto.gov/sites/default/files/documents/Claim%20drafting.pdf
  17. https://en.wikipedia.org/wiki/Claims_under_the_European_Patent_Convention
  18. https://patents.google.com/patent/EP1345920B1/en
  19. https://newdrugapprovals.org/tag/actelion/

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.